Cost-effectiveness of Empagliflozin
Jan 11, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
Examining both the clinical and the cost outcomes for patients with type 2 diabetes with established cardiovascular disease.
Using antidiabetic medications has the goal of preventing microvascular and macrovascular complications, increasing life expectancy, and improving the quality of life. One aspect that is important when determining medication regimens for patients with diabetes is the cost-effectiveness of the medication. Since diabetes is associated with increased costs due to related complications, it is important to consider these options. This study developed an economic model based on the EMPA-REG OUTCOME trial to assess clinical and cost outcomes in patients with type 2 diabetes with established cardiovascular disease....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.